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DISORDERS 
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ABSTRACT 
Cardiovascular diseases remain one of the leading causes of death globally. A lot of dietary patterns for CVD prevention 
have been proposed, but special attention is paid to functional foods. Bioactive proteins and peptides from animal sources 
are also considered tools for the prevention of CVDs. Here, 40 overweight or obese adult men and women aged between  
61 and 66 years, with a body-mass index between 28 and 61 kg.m-2, were enrolled into a randomised controlled trial of new 
meat products for specialised nutrition. Participants in the control group (n = 20) consumed a standard hyponatric low-
calorie diet for 28-30 days (10 days inpatient and 18-20 days outpatient), and in the experimental group – a low-calorie diet 
and 100g developed meat product (ratio of the porcine aorta to hearts 1:3) per day. Total cholesterol, triglyceride, 
cholesterol low-density lipoprotein, and cholesterol high-density lipoprotein levels were measured in the serum; from this, 
the atherogenic index was calculated. The positive effect of developed meat products on the serum lipid profile of patients 
during the trial was mild but noticeable. A significant reduction in cholesterol levels was noticed in the experimental group, 
by 18.2% and 14.0% after 7 – 10 and 28 – 30 days, respectively, while the cholesterol level in the control group returned to 
its original level after 28 – 30 days of dieting. The difference between the control and experimental groups was not 
significant, while data in the percentiles were. Therefore, it is more preferable to use a developed product as a component 
in diet therapy for hyperlipidaemic humans for over 28 – 30 days. Pronounced effects of the product could be linked to the 
unique proteome and peptidome of heart and aorta tissues based on organ-specific gene expression and the presence of 
tissue-specific substances. 
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INTRODUCTION 
 According to World Health Organisation data, 
cardiovascular diseases (CVDs) are the leading cause of 
death globally, taking an estimated 17.9 million lives each 
year. An unhealthy diet is one of the main risk factors for 
CVD, as well as high blood cholesterol and high blood 
sugar or glucose levels. Therefore, CVDs are often 
accompanied by metabolic syndrome and diabetes (Han 
and Lean, 2016; Saklayen, 2018). 
A lot of dietary patterns for the prevention of CVDs have 
been proposed, such as low-fat diets enriched with 
monounsaturated (MUFA) and polyunsaturated (PUFA) 
fats, low-carbohydrate diets enriched with fibres, the 
Dietary Approach to Stop Hypertension (DASH) diet 
providing more calcium, potassium, magnesium, and 
dietary fibre and less fat, saturated fatty acids (SFA), 
cholesterol, and sodium, and the Mediterranean diet 
characterised by a relatively high fat intake (40–50% of 
total daily calories), of which SFA comprises ≤8% and 
MUFA 15–25% of calories (Eilat-Adar et al., 2013; 
Anand et al., 2015; Mozaffarian, 2016). 
Composition modification (fatty acids modification, 
sodium chloride control), fermentation (formation of 
bioactive compounds) and the introduction of functional 
additives (plant components (oils, extracts, fibres), soy 
protein, natural and synthetic antioxidants, lactic acid 
bacteria, and fish oil are successfully used in functional 
food processing (Mine and Shahidi, 2006; Cencic and 
Chingwaru, 2010; Alissa and Ferns, 2012; Hui, 2012; 
Griffiths et al., 2016; Lordan et al., 2018). 
Peptides of animal origin released from milk and meat 
proteins during proteolysis, fermentation or food 
processing possess hypotensive, antioxidant, antimicrobial, 
antitumor, antithrombotic, lipid-lowering, and opioid etc. 
actions, and can be considered functional additives to food 
(Arihara, 2006; Ahhmed and Muguruma, 2010; Ryan 
et al., 2011; Udenigwe and Howard, 2013; Lafarga and 
Hayes, 2014; Bhat, Kumar and Bhat, 2015; Liu et al., 
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2016; Sánchez and Vázquez, 2017). However, tissue-
specific proteins and peptides contained natively in 
slaughter by-products have still not been well-studied. 
In previous studies, we confirmed the lipid-lowering 
effect of functional meat products derived from the porcine 
heart and aorta on hyperlipidaemic rats (Chernukha et al., 
2018; Kotenkova and Chernukha, 2019). This paper 
reports the analytical results of a randomised controlled 
trial of meat products for specialised nutrition in patients 
with cardiovascular and metabolic disorders. 
 
Scientific hypothesis  
 A wide range of tissue-specific proteins and peptides 
were identified in raw porcine heart and aorta, some of 
which were decomposed during meat product processing. 
The hypothesis that tissue-specific proteins could 
decompose into active peptides with similar biological 
action was proven in hyperlipidaemic rats that consumed 
the innovative product.  
Nevertheless, the effectiveness of the product on rodents 
and humans can vary significantly; therefore, the 
hypolipidaemic action was studied during a randomised 
controlled trial on patients with cardiovascular and 
metabolic disorders. 
 
MATERIAL AND METHODOLOGY 
 Meat products (MsP) for specialised nutrition were 
produced on ZAO "Yoshkar-Olinskiy Myasokombinat”. 
Porcine hearts were chopped with a particle size of  
2 – 3 mm and salted for 12 h. Porcine aortas were chopped 
with a particle size of 2 – 3 mm and homogenised in a 
cutter at 3000rpm for 2 – 3 min. Minced hearts with the 
juice were quantitatively transferred in the cutter and 
homogenised at 3000rpm for 6 – 8 min (ratio of the aorta 
to hearts 1:3). The obtained mince was packed in cans of 
lamister and sterilised at 115 °C and a pressure of 0.23 
MPa for 40 min. Meat products contained 17.53 ±0.95% 
protein, 3.82 ±0.13% fat, 0.305 ±0.015% sodium chloride, 
and 2.35 ±0.25% starch. 
 
Study design 
The open, prospective, and randomised study was 
conducted based on the Department of Cardiovascular 
Pathology of the Federal Research Centre of Nutrition and 
Biotechnology from June 01, 2019, to October 15, 2019. 
The study protocol was approved by the Ethics 
Committee of the Federal Research Centre of Nutrition 
and Biotechnology (Protocol No. 7 of 03.12.2018). In 
accordance with the GCP program, all participants signed 
written informed consent. 
 
Randomization and study groups 
Forty overweight or obese adult men and women aged 
between 61 and 66 years, with a body-mass index between 
28 and 61 kg.m-2, were enrolled.  
Patients were randomised into two groups by flipping a 
coin. The participants were not blinded to their group 
assignment. Participants in the control group (n = 20) 
consumed a standard hyponatric low-calorie diet (LCD) 
for 28 – 30 days (10 days inpatient and 18 – 20 days 
outpatient), and in the experimental group received LCD 
and 100g MP per day.  
 
Dietary intake  
 LCD is a diet with a significant restriction of fat and 
easily digestible carbohydrates, normal protein, and 
complex carbohydrates, with an increased amount of 
dietary fibre and a reduction of table salt (3 – 5 g/day). 
Dishes are boiled, stewed, baked, pureed, and not pureed, 
as well as steamed. The food temperature ranged from  
15 °C to 60 – 65ºC, while the free liquid is 0.8 – 1.5 L. 
Nutrition is fractional, with addition 4-6 times a day. 
Comparative characteristics of the chemical composition 
of LCD and modified diet with the inclusion of MP are 
presented in Table 1. 
 
Biochemical analysis 
 Blood samples for biochemical studies were taken on 0,  
7 – 10 and 28 – 30 days. Biochemical investigations were 
carried out on an automatic analyser BioChem FC-360 
(HTI, USA) according to the instructions supplied with the 
measurement kits (HTI, USA). Total cholesterol (TCL), 
triglyceride (TG), cholesterol low-density lipoprotein (CL 
LDL), and cholesterol high-density lipoprotein (CL HDL) 
levels were measured in serum. Atherogenic index  
(AI) = (TCL - CL HDL)/CL HDL.  
 
Statistical analysis 
STATISTICA 10.0 software was used in this study for 
the statistical analyses. The results were calculated as 
"middle value ± standard deviation" (M ±SD) and 
“percentile” (P25\75). Significant differences were tested by 
nonparametric statistical Mann-Whitney U tests for 
independent variables and Freidman ANOVA for 
dependent variables. Differences with p-values less than 
0.05 were considered as statistically significant. 
 
RESULTS AND DISCUSSION 
 The null hypothesis about the influence of control and 
experimental diets on serum lipid profile inside the group 
were checked according to Freidman’s ANOVA for all 
patients and patients with a BMI below 40 kg.m
-2
  
(ncontrol = 11, nexperimental = 10) and above 40 kg.m
-2
  
(ncontrol = 9, nexperimental = 10). The results are presented in 
Table 1. It was shown that LCD consumption (control) for 
7 – 10 days led to total cholesterol reduction by 11.2%, 
mainly due to its reduction in the serum of patients with a 
 Table 1 Comparative characteristics of the chemical composition of LCD and modified diet with the inclusion of MP. 
Diet 
Chemical composition 
Energy value, kcal/day Proteins, g/day Fat, g/day Carbohydrates, g/day 
LCD 1350.0 – 1550.0 70.0 – 80.0 60.0 – 70.0 130.0 – 150.0 
LCD+MP 1437.0 – 1682.0 86.5 – 98.0 63.0 – 76.0 131.0 – 151.5 
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BMI below 40 kg.m
-2
 by 17.7%.  
 The cholesterol level returned to its original level after 
28–30 days of dieting. Revealed changes were not 
significantly reliable. LCD with MP consumption 
(experimental) led to a statistically significant total 
cholesterol reduction by 18.2% and 14.0% after 7 – 10 and 
28 – 30 days, respectively, mainly due to its reduction in 
the serum of patients with a BMI above 40 kg.m
-2
 by 
28.4% and 12.8%, respectively. Despite the lack of 
statistical significance, it was noted that the total 
cholesterol level reduction was higher in patients with a 
BMI below 40 kg.m
-2
 and equal to 15.0% compared with 
day 0.  
Table 1 Serum lipid profile of patients during trial. 
Groups 0 days 7 – 10 days 28 – 30 days 
p-value 
(Freidman ANOVA) 
Total Cholesterol, mmol.L
-1 
Control group      
Total patients 3.829 ±0.777 3.400 ±0.695 4.025 ±1.225 0.1423 
Patients with BMI >40 kg.m
-2 
3.600 ±0.817 3.513 ±0.773 3.860 ±1.386 0.7165 
Patients with BMI <40 kg.m
-2
 4.016 ±0.726 3.307 ±0.647 4.160 ±1.127 0.1496 
Experimental group      
Total patients 4.637 ±1.411 3.791 ±1.109 3.989 ±0.955 0.0008 
Patients with BMI >40 kg.m
-2
 4.474 ±1.564 3.202 ±0.606 3.901 ±0.839 0.0018 
Patients with BMI <40 kg.m
-2
 4.800 ±1.303 4.381 ±1.208 4.078 ±1.097 0.0672 
Cholesterol LDL, mmol.L
-1
 
Control group      
Total patients 1.981 ±0.535 1.708 ±0.469 2.241 ±1.008 0.0174 
Patients with BMI >40 kg.m
-2
 2.041 ±0.479 1.769 ±0.459 2.296 ±1.193 0.3679 
Patients with BMI <40 kg.m
-2 
 1.931 ±0.596 1.658 ±0.493 2.196 ±0.888 0.0379 
Experimental group      
Total patients 2.691 ±1.151 2.089 ±0.884 2.230 ±0.697 0.0024 
Patients with BMI >40 kg.m
-2
 2.517 ±1.264 1.601 ±0.466 2.093 ±0.617 0.0018 
Patients with BMI <40 kg.m
-2
 2.864 ±1.064 2.576 ±0.951 2.367 ±0.777 0.1496 
Cholesterol HDL, mmol.L
-1
 
Control group      
Total patients 1.145 ±0.286 1.131 ±0.269 1.191 ±0.245 0.0150 
Patients with BMI >40 kg.m
-2
 0.965 ±0.297 1.066 ±0.342 1.028 ±0.231 0.1211 
Patients with BMI <40 kg.m
-2
 1.291 ±0.179 1.185 ±0.192 1.323 ±0.169 0.0116 
Experimental group      
Total patients 1.118 ±0.258 1.016 ±0.258 1.155 ±0.262 0.0106 
Patients with BMI >40 kg.m
-2
 1.147 ±0.283 1.015 ±0.201 1.193 ±0.278 0.0055 
Patients with BMI <40 kg.m
-2
 1.090 ±0.242 1.016 ±0.178 1.117 ±0.254 0.4966 
Triglycerides, mmol.L
-1
 
Control group      
Total patients 1.039 ±0.433 1.000 ±0.452 1.098 ±0.493 0.2466 
Patients with BMI >40 kg.m
-2
 1.193 ±0.541 1.157 ±0.404 1.147 ±0.492 0.8948 
Patients with BMI <40 kg.m
-2
 0.913 ±0.290 0.872 ±0.465 1.058 ±0.514 0.1482 
Experimental group      
Total patients 1.919 ±0.987 1.689 ±0.777 1.585 ±0.866 0.3499 
Patients with BMI >40 kg.m
-2
 1.760 ±0.781 1.600 ±0.833 1.341 ±0.482 0.9048 
Patients with BMI <40 kg.m
-2
 2.078 ±1.179 1.778 ±0.751 1.829 ±0.104 0.2725 
Serum atherogenic index 
Control group      
Total patients 2.494 ±0.798 2.085 ±0.628 2.465 ±1.048 0.0863 
Patients with BMI >40 kg.m
-2
 2.924 ±0.837 2.398 ±0.603 2.830 ±1.225 0.1211 
Patients with BMI <40 kg.m
-2
 2.141 ±0.587 1.828 ±0.545 2.167 ±0.817 0.1777 
Experimental group      
Total patients 3.192 ±0.968 2.756 ±0.936 2.540 ±0.864 0.0863 
Patients with BMI >40 kg.m
-2
 2.959 ±1.107 2.190 ±0.503 2.352 ±0.707 0.2725 
Patients with BMI <40 kg.m
-2
 3.425 ±0.795 3.320 ±0.941 2.728 ±0.999 0.2019 
Note: p <0.05 mean that diet consumption influence on lipid parameter in serum. 
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In the control group, a statistically significant cholesterol 
LDL reduction by 13.8% was noticed after 7 – 10 days, 
mainly due to its reduction in the serum of patients with a 
BMI below 40 kg.m
-2
 by 14.1%. LDL cholesterol level 
decline was also marked in the serum of experimental 
patients and was equal to 22.4% after 7 – 10 days, mainly 
due to its reduction in the serum of patients with a higher 
BMI of 40 kg.m
-2
 by 36.4%. The cholesterol LDL level 
returned to its original level in both groups after 28 – 30 
days of dieting. The same tendency was noticed 
concerning the cholesterol HDL level.  
There were no significantly reliable changes to 
triglyceride levels and serum atherogenic index in both 
groups. However, after 7–10 days after the diets, a 
decrease in triglyceride levels in the control group 
amounted to only 3.9% and returned to its original level 
after 28 – 30 days, while the reduction in experimental 
patients was equal to 12.0% and continued to reduce until 
28 – 30 days to 17.4%. The same tendency was noticed 
concerning serum atherogenic index (AI). Also, 7 – 10 
days after the diets, the decrease in AI in the control group 
amounted to 16.4% and returned to its original level after 
28 – 30 days, while the reduction was equal to 13.7% in 
experimental patients and continued to reduce until 28 – 
30 days to 20.4%. 
Cholesterol levels on days 0, 7 – 10 and 28 – 30 days 
were compared between the control and experimental 
groups according to the Mann-Whitney U test. There were 
no significantly reliable changes in cholesterol levels in the 
two groups for all patients and patients with a BMI higher 
40 kg.m
-2
. Cholesterol LDL on day 0 in the serum of 
experimental patients with a BMI lower than 40 kg.m
-2
 
was higher than in the control group by 48.3% (p <0.05), 
while cholesterol HDL was lower by 15.7%; therefore, 
there was no difference between total cholesterol levels.  
 
 After 7 – 10 days, the cholesterol LDL in the serum of 
experimental patients with a BMI below 40 kg.m
-2
 was still 
higher than in the control group by 55.4% (p <0.05), but 
returned to the original level in both groups after 28 – 30 
days of dieting. 
 
 Figure 1 Cholesterol distribution in the serum of patients during the trial. Note: 
* 
- significant difference between the 
control and experimental groups (p <0.05) 
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With such heterogeneity of groups, it is advisable to 
consider changes in the lipid profile in dynamics and 
compare changes in parameters between groups. Dynamics 
were evaluated between 0 day and 7 – 8 days and 0 day 
and 28 – 30 days and are presented in Table 2 in 
percentiles (P25\75); statistical differences were calculated 
according to Mann-Whitney U tests. 
There were no significantly reliable changes in Δ total 
cholesterol after 7 – 10 days of diet consumption, but after 
28 – 30 days in the serum of experimental patients it was 
significantly lower than in the control, mainly due to LDL 
cholesterol reduction especially in patients with a BMI 
below 40 kg.m
-2
. The same tendency was noticed 
concerning Δ triglycerides. There was still no significantly 
reliable changes in the Δ serum atherogenic index, despite 
its remarkable reduction in the experimental group by 
13.7% and 20.4% at 7 – 10 and 28 – 30 days, respectively 
(Table 1). Nevertheless, a positive effect of MP on the 
serum lipid profile of patients during the trial is noticeable. 
In a previous study it was shown that meat products 
characterised by milder hypolipidaemic action compared 
with native raw material or isolated active fractions; a 
slight effect was observed after 28 days of consumption by 
hyperlipidemic rats, while a significant effect was only 
seen after 42 days of consumption (Kotenkova and 
Chernukha, 2019).  
The pronounced effect of meat product could be linked 
to the unique proteome and peptidome of the heart and 
aorta tissues based on organ-specific gene expression and 
the presence of tissue-specific substances (Fagerberg et 
al., 2014; Breschi et al., 2016; Guschanski, Warnefors 
and Kaessmann, 2017; Sonawane et al., 2017; Barbeira 
et al., 2018). Previously, we also observed that sterilisation 
led to the decomposition of most parts of the target tissue-
specific proteins and peptides into active peptides with 
apparently similar biological actions or retained residual 
activity (Chernukha et al., 2016; Chernukha et al., 
2018; Kotenkova and Chernukha, 2019). 
On the other hand, numerous authors also considered 
animal proteins as abundant sources of functional peptides, 
including those which demonstrated a lipid-lowering effect 
(Bauchart et al., 2006; Ahhmed and Muguruma, 2010; 
Toldrá et al., 2012; Udenigwe and Howard, 2013; 
Lafarga and Hayes, 2014; Cicero, Fogacci and Colletti, 
2017). Nakade et al. (2009) revealed that cattle heart 
protein hydrolysate could suppress cholesterol absorption 
in Caco-2 cells.  
It is known that aorta tissue is enriched with collagen and 
elastin, while collagen-derived peptides have been better 
studied and are characterised by their lipid-lowering effect 
(Koyama and Kusubata, 2013; Hongdong and Bo, 
2017; Tometsuka et al., 2017; Tomosugi et al., 2017; 
Yazaki et al., 2017; Arrutia et al., 2017; Wahart et al., 
2019). In this regard, aorta tissue is a good source of 
glyproline peptides with hypolipidaemic action (Lyapina 
et al., 2015; Shabalina Lyapina et al., 2015; Myasoedov 
et al., 2016). Presumably, active peptides could be 
generated both during meat product processing and 
digestion processes.  
 
CONCLUSION 
 The positive effect of developed meat products on the 
serum lipid profile of patients during the trial was mild but 
noticeable. Presumably, it is more preferable to use this as 
a component in a diet therapy for hyperlipidaemic humans 
for 28 – 30 days. Earlier, the same effect was revealed on 
hyperlipidaemic rodents, which confirms the lipid 
decreasing ability effect of innovative products and can be 
recommended as part of a diet to fight CVD. The 
pronounced effect of the product could be linked to the 
unique proteome and peptidome of the heart and aorta 
tissues based on organ-specific gene expression and the 
presence of tissue-specific substances. 
 Table 2 Dynamics of serum lipid profile changes in patients during the trial. 
Days 
Control group Experimental group 
Total 
BMI  
>40 kg.m
-2 
BMI  
<40 kg.m
-2
 
Total 
BMI  
>40 kg.m
-2
 
BMI  
<40 kg.m
-2
 
Δ total Cholesterol, P25/75 
7 – 10  -0.024/1.314 -0.380/1.211 -0.008/1.502 0.349/0.784 0.372/2.139 0.325/0.652 
28 – 30  -0.597/0.368 -0.556/0.117 -0.608/0.953 -0.218/1.631* -0.406/1.564 -0.045/1.698 
Δ Cholesterol LDL, P25/75 
7 – 10  -0.094/0.756 -0.163/0.753 -0.025/1.010 0.244/0.687 0.279/1.682 0.110/0.627 
28 – 30  -0.465/0.034 -0.325/0.050 -0.642/0.017 -0.142/1.144* -0.399/1.274 -0.114/0.977* 
Δ Cholesterol HDL, P25/75 
7 – 10  -0.036/0.177 -0.038/0.153 0.045/0.186 -0.014/0.206 0.002/0.223 -0.028/0.141 
28 – 30  -0.186/0.077 -0.173/-0.019 -0.198/0.082 -0.148/0.047 -0.155/0.074 -0.137/0.020 
Δ Triglycerides, P25/75 
7 – 10  -0.083/0.218 -0.226/0.246 -0.071/0.216 -0.273/0.421 -0.215/0.395 -0.303/0.446 
28 – 30  -0.174/0.125 -0.081/0.081 -0.296/0.168 -0.148/0.794* -0.183/0.862 -0.051/0.606* 
Δ Serum atherogenic index, P25/75 
7 – 10  -0.155/0.730 -0.207/0.944 -0.103/0.713 -0.023/0.822 -0.017/1.493 -0.158/0.605 
28 – 30  -0.537/0.703 0.101/0.475 -0.693/0.822 -0.021/1.489 -0.040/1.642 -0.002/1.444 
Note: 
* 
-significant differences between the control and experimental groups (p <0.05) 
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